Related Experiment Video
Updated: Feb 20, 2026
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.
Enrique Gómez Gómez1, José Valero Rosa1, Julia Carrasco Valiente1
1Urology Department, Reina Sofia University Hospital /Córdoba University, Cordoba, Spain; Radiology Department, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC)/Reina Sofia University Hospital, Cordoba, Spain.
This study introduces a new fusion device for prostate cancer biopsies, improving the detection of significant cancer (sig PCa) by combining MRI and ultrasound imaging. Further research is needed to confirm its statistical significance.
Area of Science:
- Urology
- Medical Imaging
- Oncology
Background:
- Persistent suspicion of prostate cancer often necessitates repeat biopsies.
- Multiparametric magnetic resonance imaging (mpMRI) aids in identifying suspicious prostate lesions.
- Real-time image fusion technology aims to improve biopsy accuracy.
Purpose of the Study:
- To describe the technique of transrectal biopsy using a novel device that fuses mpMRI and ultrasound images in real time.
- To evaluate the initial experience and diagnostic yield of this fusion-guided biopsy technique.
Main Methods:
- Patients with prior negative biopsies and suspicious mpMRI findings were selected.
- A fusion biopsy technique combining mpMRI and ultrasound was employed, alongside standard systematic biopsies.
- Significant prostate cancer (sig PCa) was defined by Epstein criteria (standard) and Gleason grade ≥7 with ≥5 mm positive core length (fusion target).
Main Results:
- The fusion target biopsy diagnosed sig PCa in 37.5% of patients, compared to 25% with standard biopsy (P=.08).
- The probability of cancer diagnosis correlated with Prostate Imaging Reporting and Data System scores (k=0.45, P=.08).
- A median of 4 cores were taken with fusion biopsy versus 12 with standard biopsy.
Conclusions:
- The new fusion device is a valuable tool for guiding biopsies in patients with mpMRI-identified target lesions.
- This technique shows potential for increasing the detection of significant prostate cancer.
- A larger patient cohort is necessary to establish statistically significant differences in detection rates.
